Search results for " diagnosis."

showing 10 items of 1334 documents

Exosomes in cancer theranostic: Diamonds in the rough

2017

IF 3.306; International audience; During the last 10 years, exosomes, which are small vesicles of 50-200 nm diameter of endosomal origin, have aroused a great interest in the scientific and clinical community for their roles in intercellular communication in almost all physiological and pathological processes. Most cells can potentially release these nanovesicles that share with the parent cell a similar lipid bilayer with transmembrane proteins and a panel of enclosed soluble proteins such as heat shock proteins and genetic material, thus acting as potential nanoshuttles of biomarkers. Exosomes surface proteins allow their targeting and capture by recipient cells, while the exosomes' conte…

0301 basic medicineEndosomeReviewexosomes[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyModels BiologicalTheranostic NanomedicineMetastasis03 medical and health sciencesCellular and Molecular NeuroscienceDrug Delivery SystemsNeoplasmsHeat shock proteincancer diagnosisBiomarkers TumormedicineAnimalsHumansTumor microenvironment[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyCancerCell Biologymedicine.diseasePrimary tumorMicrovesicles3. Good healthCell biology030104 developmental biologyTumor progressionheat shock proteinscancer therapy
researchProduct

Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma

2019

ABSTRACTCutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although most cSCCs have good prognosis, a subgroup of high-risk cSCC has a higher frequency of recurrence and mortality. Therefore, the identification of molecular risk factors associated with this aggressive subtype is of major interest. In this work we carried out a global-scale approach to investigate the DNA-methylation profile in patients at different stages, from premalignant actinic keratosis to low-risk invasive and high-risk non-metastatic and metastatic cSCC. The results showed massive non-sequential changes in DNA-methylome and identified a minimal methylation signature that discriminates bet…

0301 basic medicineEpigenomicsMaleSkin NeoplasmsDiseaseBiochemistryActinic KeratosisGenomeEpigenesis Genetic0302 clinical medicineRisk FactorsMedicine and Health SciencesSkin TumorsAged 80 and overMultidisciplinaryDNA methylationQRSquamous Cell CarcinomasMethylationMiddle AgedPrognosisChromatinNucleic acidsGene Expression Regulation NeoplasticKeratosis ActinicOncology030220 oncology & carcinogenesisDNA methylationCarcinoma Squamous CellDisease ProgressionMedicineEpigeneticsFemaleDNA modificationChromatin modificationResearch ArticleChromosome biologyCell biologyCutaneous squamous cell carcinomaKeratosisScienceDermatologyBiologyCarcinomas03 medical and health sciencesDiagnostic MedicineCarcinomaGeneticsCancer Detection and DiagnosismedicineHumansEpigeneticsAgedNeoplasm StagingTreatment GuidelinesHealth Care PolicyBiology and life sciencesActinic keratosisCancers and NeoplasmsDNAmedicine.diseaseDNA FingerprintingDna methylation profilingHealth Care030104 developmental biologyCancer researchGene expressionNeoplasm Recurrence LocalSkin cancerGenome-Wide Association Study
researchProduct

Intrasinusoidal HHV8-EBV–Positive Large B-Cell Lymphoma With Features of Germinotropic Lymphoproliferative Disorder

2020

Germinotropic lymphoproliferative disorder (GLPD) is a poorly characterized lymphoproliferative entity, recently included in the World Health Organization classification of hematolymphoid neoplasms. The histological pattern of this disease comprises monotypic plasmablasts that involve the germinal centers of the lymphoid follicles (germinotrophism), forming confluent aggregates positive for both human herpes virus type 8 (HHV8) and Epstein-Barr virus. Currently, after 17 years of its first description, only 18 cases have been reported. In this article, we describe a case of a GLPD presenting in an immunocompetent 79-year-old woman with localized axillary lymphadenopathy, showing a prominen…

0301 basic medicineEpstein-Barr Virus InfectionsHerpesvirus 4 HumanPathologymedicine.medical_specialtyLymphoma B-Cellmedicine.disease_causePathology and Forensic Medicine03 medical and health sciences0302 clinical medicinemedicineAxillary LymphadenopathyHumansB-cell lymphomaAnaplastic large-cell lymphomaAgedbusiness.industryGerminal centerHerpesviridae Infectionsmedicine.diseaseEpstein–Barr virusLymphoproliferative DisordersLymphoma030104 developmental biologyPleomorphism (cytology)030220 oncology & carcinogenesisHerpesvirus 8 HumanFemaleSurgeryLymph NodesAnatomyDifferential diagnosisbusinessInternational Journal of Surgical Pathology
researchProduct

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

2018

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as a…

0301 basic medicineEvidence-based practiceImmunologyInflammationGuidelines as TopicSystemic lupus erythematosuBioinformaticsAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis;Autoimmune DiseaseAutoimmune DiseasesRheumatic Disease03 medical and health sciencesTherapeutic approachSystemic sclerosiEconomica0302 clinical medicineImmune systemSystemic lupus erythematosusAntiphospholipid syndromeEarly DiagnosiRheumatic DiseasesAntiphospholipid syndromemedicineImmunology and AllergyHumansRheumatoid arthritisRheumatoid arthritiAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis030203 arthritis & rheumatologySpondyloarthritidebusiness.industryBiomarkermedicine.diseaseClinical diseaseSjögren syndromeAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Autoimmune Diseases; Biomarkers; Early Diagnosis; Evidence-Based Practice; Guidelines as Topic; Humans; Rheumatic Diseases; Immunology and Allergy; ImmunologySettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisRheumatoid arthritisEvidence-Based PracticeBiomarker (medicine)SpondyloarthritidesSystemic sclerosismedicine.symptombusinessBiomarkersHuman
researchProduct

Identification of novel mutations in L1CAM gene by a DHPLC-based assay

2016

X-linked hydrocephalus, MASA syndrome, X-linked complicated Spastic Paraplegia Type I, and X-linked partial agenesis of the corpus callosum are rare diseases mainly affecting male population and broadly referred as L1 syndrome, caused by mutations in the L1CAM gene. In the present study 36 boys and a male fetus whose clinical features were consistent with L1 syndrome were analyzed by dHPLC assay and direct sequencing of L1CAM gene. Sequence analysis of the 14 different aberrant dHPLC elution profiles demonstrated that six of them were associated with already reported polymorphisms, four with previously described causative variants while the remaining four represented novel L1CAM mutations. …

0301 basic medicineGeneticsCRASH syndromeHydrocephaluSequence analysisSpastic paraplegiaMASA syndromeL1-diseaseBiologyCorpus callosummedicine.diseaseBiochemistryHuman geneticsHydrocephalus03 medical and health sciences030104 developmental biologyIntellectual disabilityGeneticsmedicineAdducted thumbDifferential diagnosisL1 syndromeMolecular BiologyGenes & Genomics
researchProduct

Genetic Analysis of Human Preimplantation Embryos

2016

Preimplantation development comprises the initial stages of mammalian development, before the embryo implants into the mother's uterus. In normal conditions, after fertilization the embryo grows until reaching blastocyst stage. The blastocyst grows as the cells divide and the cavity expands, until it arrives at the uterus, where it "hatches" from the zona pellucida to implant into the uterine wall. Nevertheless, embryo quality and viability can be affected by chromosomal abnormalities, most of which occur during gametogenesis and early embryo development; human embryos produced in vitro are especially vulnerable. Therefore, the selection of chromosomally normal embryos for transfer in assis…

0301 basic medicineGeneticsPregnancyanimal structures030219 obstetrics & reproductive medicinemedicine.diagnostic_testGenetic disorderEmbryoBiologymedicine.diseasePreimplantation genetic diagnosisAndrology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureembryonic structuresmedicineBlastocystZona pellucidaEmbryo qualityGenetic testing
researchProduct

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 3…

2017

Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning.Objective: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015.Evidence Review: Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was calculated by dividing mortality estimates through the modeled MI ratio…

0301 basic medicineGerontologyCancer ResearchPopulationArticle03 medical and health sciences0302 clinical medicineBreast cancerGlobal healthcancerMedicineDisability-adjusted life yeareducationDisease burdeneducation.field_of_studyestimate mortalityCancer preventioncancer preventionbusiness.industryMortality rate1. No povertymedicine.disease3. Good health030104 developmental biologyYears of potential life lostOncology030220 oncology & carcinogenesisbusinessearly diagnosisDemography
researchProduct

Sperm chromosomal abnormalities and their contribution to human embryo aneuploidy.

2018

In this work we reviewed 18 years of experience using fluorescence in situ hybridization (FISH) for sperm aneuploidy testing. We evaluated parameters associated with increased numerical sperm chromosome abnormalities and determined the male contribution to embryo aneploidies in terms of reproductive outcome by increased sperm aneuploidy. This retrospective study analyzed data from 2008 sperm samples of infertile males undergoing FISH analysis because of clinical history of repetitive implantation failure, recurrent miscarriage, impaired sperm parameters, or mixed causes. Sperm concentration was the only sperm parameter associated with FISH results—we observed a gradual increase of abnormal …

0301 basic medicineInfertilityMaleendocrine systemmedicine.medical_treatmentAneuploidyFertilization in VitroBiologyIntracytoplasmic sperm injectionMale infertilityAndrology03 medical and health sciences0302 clinical medicinePregnancymedicineHumansSperm Injections IntracytoplasmicPrecision Medicinereproductive and urinary physiologyIn Situ Hybridization FluorescenceInfertility MalePreimplantation DiagnosisRetrospective StudiesChromosome AberrationsComparative Genomic Hybridization030219 obstetrics & reproductive medicineIn vitro fertilisationmedicine.diagnostic_testSperm Counturogenital systemHigh-Throughput Nucleotide SequencingEmbryoCell BiologyGeneral MedicineOligospermiamedicine.diseaseAneuploidySpermSpermatozoa030104 developmental biologyReproductive MedicineSperm MotilityFemaleFluorescence in situ hybridizationBiology of reproduction
researchProduct

Paving the way for a gold standard of care for infertility treatment: improving outcomes through standardization of laboratory procedures.

2016

Infertility affects over 70 million couples globally. Access to, and interest in, assisted reproductive technologies is growing worldwide, with more couples seeking medical intervention to conceive, in particular by IVF. Despite numerous advances in IVF techniques since its first success in 1978, almost half of the patients treated remain childless. The multifactorial nature of IVF treatment means that success is dependent on many variables. Therefore, it is important to examine how each variable can be optimized to achieve the best possible outcomes for patients. The current approach to IVF is fragmented, with various protocols in use. A systematic approach to establishing optimum best pra…

0301 basic medicineInfertilityMalemedicine.medical_specialtyStandardizationReproductive Techniques AssistedBest practiceReproductive technology03 medical and health sciencesEndometrium0302 clinical medicineIntervention (counseling)medicineHumansIntensive care medicineBirth RateInfertility MalePreimplantation DiagnosisGynecologyIvf treatment030219 obstetrics & reproductive medicinebusiness.industryClinical Laboratory TechniquesGold standardObstetrics and GynecologyStandard of Caremedicine.diseaseCulture Media030104 developmental biologyTreatment OutcomeReproductive MedicineFemalebusinessLive birthInfertility FemaleDevelopmental BiologyReproductive biomedicine online
researchProduct

Second-generation preimplantation genetic testing for aneuploidy in assisted reproduction: a SWOT analysis.

2019

Second-generation preimplantation genetic testing for aneuploidy (PGT-A 2.0) in patients with an unfavourable reproductive and IVF prognosis is becoming common practice, with the aim of improving reproductive outcomes. However, there is still no clear evidence on the possible advantages and drawbacks with regard to this procedure. In this discussion paper, based on a SWOT (strengths, weaknesses, opportunities, threats) analysis, the different aspects of this strategy are evaluated. Current evidence suggests that PGT-A 2.0 should not at present have an indiscriminate application, but it might be indicated in cases in which the risk of aneuploidy is increased.

0301 basic medicineInfertilityPregnancy RateReproduction (economics)AneuploidyBlastocyst biopsy03 medical and health sciences0302 clinical medicinePregnancymedicineLive birthHumansIn patientGenetic TestingSWOT analysisPreimplantation DiagnosisGenetic testing030219 obstetrics & reproductive medicinePreimplantation genetic testingmedicine.diagnostic_testbusiness.industryAssisted reproductionObstetrics and Gynecologymedicine.diseaseAneuploidyImplantationAbortion Spontaneous030104 developmental biologyReproductive MedicineRisk analysis (engineering)InfertilityFemalebusinessLive birthDevelopmental Biology
researchProduct